\-\ Texto\\:\\ \ \(0\)\
\-\ vitals\\:\\ t\\=35\\.9\\,\\ p\\=63\\,\\ r\\=20\\ bp\\=106\\/41\ \(0\)\
\-\ pt\\ is\\ follows\\ simple\\ commands\\,\\ continues\\ to\\ be\\ non\\-verbal\\,\\ perrla\\,\\ neurological\\ exam\\ is\\ grossly\\ intact\\.\\ the\\ pt\\ has\\ numerous\\ scars\\ on\\ her\\ extremities\\,\\ sebaceous\\ adenomas\\ on\\ her\\ face\\,\\ as\\ well\\ as\\ a\\ shagreen\\ patch\\ on\\ her\\ forehead\\.\\ \\ there\\ are\\ areas\\ of\\ cutaneous\\ hyperpigmentation\\ on\\ her\\ back\\.\ \(0\)\
\-\ the\\ main\\ complication\\ of\\ tuberous\\ sclerosis\\ requiring\\ long\\ term\\ therapy\\ is\\ seizure\\ disorders\\,\\ as\\ was\\ this\\ case\\ with\\ our\\ patient\\.\\ \\ she\\ was\\ placed\\ on\\ antiepileptic\\ medication\\ and\\ has\\ spent\\ much\\ of\\ her\\ childhood\\ in\\ institutions\\ due\\ to\\ her\\ behavioral\\ and\\ developmental\\ delays\\ as\\ well\\ as\\ poor\\ family\\ support\\.\\ \\ in\\ oct\\ 2006\\ she\\ had\\ a\\ peg\\ tube\\ placed\\ for\\ poor\\ feeding\\ and\\ is\\ being\\ closely\\ monitored\\ by\\ her\\ pcp\\ and\\ a\\ neurologist\\.\\ \\ standards\\ currently\\ suggest\\ follow\\-up\\ mris\\ every\\ 1\\-3\\ years\\ in\\ children\\ with\\ tuberous\\ sclerosis\\.\\ options\\ for\\ treatment\\ outside\\ of\\ antiepileptic\\ medications\\ include\\ immunosuppressive\\ therapy\\,\\ surgical\\ resection\\ such\\ as\\ focal\\ cortical\\ resection\\,\\ corpus\\ callosotomy\\ \\,\\ or\\ vagal\\ stimulation\\.\\ \\ since\\ subependymal\\ giant\\ cell\\ astrocytomas\\ are\\ associated\\ with\\ tuberous\\ sclerosis\\ and\\ can\\ cause\\ hydrocephalus\\,\\ surgical\\ resection\\ may\\ be\\ indicated\\.\ \(0\)\
\-\ mri\\ of\\ the\\ brain\\ w\\/o\\ iv\\ contrast\\.\\ \\ the\\ \\ ventricles\\ \\ are\\ increased\\ \\ slightly\\ \\ in\\ \\ size\\ \\ which\\ most\\ likely\\ represent\\ \\ mild\\ \\ atrophy\\.\\ \\ \\ \\ approximately\\ six\\ subependymal\\ lesions\\ \\ are\\ \\ identified\\ \\ in\\ the\\ lateral\\ ventricles\\ bilaterally\\ with\\ enhancement\\ \\ of\\ \\ the\\ \\ largest\\ \\ lesion\\ \\ in\\ \\ the\\ right\\ \\ lateral\\ \\ ventricle\\ \\ which\\ \\ measures\\ \\ approximately\\ \\ 1\\.1\\ \\ cm\\ \\ in\\ \\ its\\ greatest\\ \\ diameter\\.\\ \\ \\ these\\ appear\\ unchanged\\ from\\ previous\\ studies\\.\\ \\ \\ noted\\ \\ are\\ \\ the\\ \\ multiple\\ \\ areas\\ \\ of\\ \\ abnormal\\ \\ t2\\ \\ prolongation\\ \\ scattered\\ \\ throughout\\ \\ the\\ cerebral\\ \\ hemispheres\\.\\ \\ \\ \\ these\\ \\ are\\ \\ grossly\\ \\ unchanged\\ \\ when\\ compared\\ \\ with\\ previous\\ \\ studies\\.\\ \\ \\ there\\ is\\ no\\ increase\\ \\ in\\ \\ the\\ extra\\-axial\\ \\ fluid\\.\\ \\ \\ \\ there\\ \\ is\\ \\ no\\ \\ evidence\\ \\ of\\ \\ cerebellar\\ \\ ectopia\\.\\ \\ \\ \\ the\\ anterior\\ \\ pituitary\\ \\ is\\ noted\\ \\ to\\ \\ be\\ \\ concaved\\ \\ but\\ \\ is\\ \\ grossly\\ \\ unchanged\\ \\ when\\ \\ compared\\ \\ with\\ \\ previous\\ \\ studies\\.\\ \\ \\ \\ the\\ \\ corpus\\ \\ callosum\\ \\ is\\ \\ somewhat\\ \\ thin\\.\ \(0\)\
\-\ tuberous\\ sclerosis\\ \\(bourneville\\ disease\\)\ \(0\)\
\-\ complex\\ partial\\ seizures\\ \ \(2\)\
\-\ tuberous\\ sclerosis\ \(40\)\
\-\ hydrocephalus\\ \ \(74\)\
\-\ lennox\\-gastaut\\ syndrome\\ \ \(0\)\
\-\ giant\\ cell\\ astrocytoma\ \(5\)\
\-\ 16\\ y\\/o\\ white\\ female\\ who\\ presented\\ to\\ the\\ er\\ with\\ her\\ mother\\ with\\ c\\/o\\ increasing\\ seizure\\ activity\\,\\ increased\\ self\\-mutilation\\,\\ and\\ violence\\ towards\\ others\\.\\ \\ pt\\ has\\ longstanding\\ hx\\ of\\ problems\\ since\\ birth\\ to\\ include\\ autism\\,\\ mental\\ retardation\\,\\ \\ developmental\\ delay\\,\\ as\\ well\\ as\\ seizure\\ disorder\\.\\ the\\ pt\\ is\\ non\\-verbal\\.\\ the\\ patient\\ was\\ being\\ followed\\ at\\ another\\ facility\\,\\ however\\,\\ due\\ to\\ a\\ recent\\ move\\,\\ her\\ family\\ now\\ wishes\\ to\\ have\\ her\\ care\\ in\\ your\\ facility\\.\ \(0\)\
\-\ as\\ is\\ the\\ case\\ with\\ more\\ than\\ 90\\ percent\\ of\\ tuberous\\ sclerosis\\ patients\\ with\\ brain\\ involvement\\,\\ this\\ patient\\ presented\\ to\\ the\\ er\\ with\\ convulsions\\.\\ \\ though\\ her\\ underlying\\ hx\\ of\\ seizures\\ disorder\\ complicates\\ the\\ picture\\,\\ it\\ is\\ likely\\ that\\ some\\ of\\ the\\ problems\\ she\\ is\\ having\\ are\\ manifestation\\ of\\ her\\ tuberous\\ sclerosis\\.\\ \\ in\\ addition\\,\\ this\\ patient\\,\\ like\\ 50\\-85\\ percent\\ of\\ those\\ affected\\ by\\ tuberous\\ sclerosis\\ has\\ severe\\ developmental\\ delay\\.\\ \\ she\\ also\\ had\\ the\\ skin\\ manifestation\\ that\\ are\\ characteristic\\ in\\ more\\ than\\ 80\\ percent\\ of\\ patient\\'s\\ to\\ include\\ shagreen\\ patches\\ and\\ sebaceous\\ adenomas\\ on\\ her\\ face\\.\\ \\ this\\ patient\\'s\\ condition\\ was\\ being\\ managed\\ conservatively\\ with\\ antiepileptic\\ medication\\ and\\ routine\\ follow\\-up\\ mris\\.\\ interestingly\\,\\ within\\ the\\ past\\ year\\ the\\ patient\\ also\\ had\\ renal\\ us\\ done\\ due\\ to\\ possible\\ renal\\ cysts\\ versus\\ tumors\\,\\ which\\ can\\ be\\ found\\ in\\ up\\ to\\ 80\\ percent\\ of\\ patients\\ with\\ tuberous\\ sclerosis\\.\\ \\ however\\,\\ at\\ the\\ time\\ of\\ this\\ posting\\,\\ the\\ final\\ results\\ are\\ not\\ known\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ tuberous\\:\\ 0\\.3371814847470367\ \(0\)\
\-\ her\\:\\ 0\\.3051217242756899\ \(0\)\
\-\ sclerosis\\:\\ 0\\.24083542544885325\ \(0\)\
\-\ the\\:\\ 0\\.17991244421846683\ \(0\)\
\-\ antiepileptic\\:\\ 0\\.1585360854934754\ \(0\)\
\-\ percent\\:\\ 0\\.1486136098343236\ \(0\)\
\-\ as\\:\\ 0\\.1358347535033704\ \(0\)\
\-\ is\\:\\ 0\\.13375039132302385\ \(0\)\
\-\ are\\:\\ 0\\.12830111469116245\ \(0\)\
\-\ unchanged\\:\\ 0\\.1254617167075924\ \(0\)\
\-\ of\\:\\ 0\\.12498506308181738\ \(0\)\
\-\ in\\:\\ 0\\.1121510017883491\ \(0\)\
\-\ shagreen\\:\\ 0\\.11103150076703161\ \(0\)\
\-\ pt\\:\\ 0\\.10814824918444797\ \(0\)\
\-\ grossly\\:\\ 0\\.10811284935772834\ \(0\)\
\-\ to\\:\\ 0\\.1033135942696789\ \(0\)\
\-\ developmental\\:\\ 0\\.09746337503896693\ \(0\)\
\-\ with\\:\\ 0\\.09563392006787907\ \(0\)\
\-\ seizure\\:\\ 0\\.09378637260030608\ \(0\)\
\-\ sebaceous\\:\\ 0\\.0927712632368294\ \(0\)\
\-\ mris\\:\\ 0\\.0927712632368294\ \(0\)\
\-\ she\\:\\ 0\\.08945542469074652\ \(0\)\
\-\ adenomas\\:\\ 0\\.08743048613211468\ \(0\)\
\-\ patient\\:\\ 0\\.08553488308051432\ \(0\)\
\-\ manifestation\\:\\ 0\\.08540001691285451\ \(0\)\
\-\ previous\\:\\ 0\\.08516345635492238\ \(0\)\
\-\ studies\\:\\ 0\\.08267631878721643\ \(0\)\
\-\ subependymal\\:\\ 0\\.08005923980813981\ \(0\)\
\-\ being\\:\\ 0\\.07853841051092712\ \(0\)\
\-\ facility\\:\\ 0\\.07451102570662715\ \(0\)\
\-\ resection\\:\\ 0\\.07224641264702536\ \(0\)\
\-\ medication\\:\\ 0\\.06944756362500927\ \(0\)\
\-\ delay\\:\\ 0\\.06889865182377851\ \(0\)\
\-\ has\\:\\ 0\\.0686414695942897\ \(0\)\
\-\ corpus\\:\\ 0\\.06850147669654998\ \(0\)\
\-\ hx\\:\\ 0\\.06837170247376367\ \(0\)\
\-\ on\\:\\ 0\\.06807867051274359\ \(0\)\
\-\ face\\:\\ 0\\.06774134406038307\ \(0\)\
\-\ include\\:\\ 0\\.06705941559705415\ \(0\)\
\-\ giant\\:\\ 0\\.06702269437113909\ \(0\)\
\-\ ventricles\\:\\ 0\\.066013283275564\ \(0\)\
\-\ problems\\:\\ 0\\.06517668615206068\ \(0\)\
\-\ due\\:\\ 0\\.06478587973781502\ \(0\)\
\-\ this\\:\\ 0\\.06454670991389196\ \(0\)\
\-\ disorder\\:\\ 0\\.06355787471906381\ \(0\)\
\-\ poor\\:\\ 0\\.06337987232013502\ \(0\)\
\-\ and\\:\\ 0\\.06210518438648956\ \(0\)\
\-\ hydrocephalus\\:\\ 0\\.06133678021819807\ \(0\)\
\-\ seizures\\:\\ 0\\.06133678021819807\ \(0\)\
\-\ be\\:\\ 0\\.060960762533879484\ \(0\)\
\-\ compared\\:\\ 0\\.06074468156823015\ \(0\)\
\-\ family\\:\\ 0\\.05911307559603872\ \(0\)\
\-\ 80\\:\\ 0\\.05861122529528196\ \(0\)\
\-\ placed\\:\\ 0\\.05854981736557483\ \(0\)\
\-\ callosotomy\\:\\ 0\\.05741042121370902\ \(0\)\
\-\ concaved\\:\\ 0\\.05741042121370902\ \(0\)\
\-\ convulsions\\:\\ 0\\.05741042121370902\ \(0\)\
\-\ posting\\:\\ 0\\.05741042121370902\ \(0\)\
\-\ er\\:\\ 0\\.056199435374284665\ \(0\)\
\-\ had\\:\\ 0\\.05615458437203529\ \(0\)\
\-\ up\\:\\ 0\\.05575172032871565\ \(0\)\
\-\ bourneville\\:\\ 0\\.055515750383515805\ \(0\)\
\-\ violence\\:\\ 0\\.055515750383515805\ \(0\)\
\-\ well\\:\\ 0\\.05457310330747416\ \(0\)\
\-\ since\\:\\ 0\\.05442775595396269\ \(0\)\
\-\ standards\\:\\ 0\\.05404612951344363\ \(0\)\
\-\ autism\\:\\ 0\\.05404612951344363\ \(0\)\
\-\ wishes\\:\\ 0\\.05404612951344363\ \(0\)\
\-\ complicates\\:\\ 0\\.05404612951344363\ \(0\)\
\-\ behavioral\\:\\ 0\\.05284536183115846\ \(0\)\
\-\ immunosuppressive\\:\\ 0\\.05284536183115846\ \(0\)\
\-\ was\\:\\ 0\\.05237249943664611\ \(0\)\
\-\ hyperpigmentation\\:\\ 0\\.051830127221528376\ \(0\)\
\-\ delays\\:\\ 0\\.051830127221528376\ \(0\)\
\-\ peg\\:\\ 0\\.051830127221528376\ \(0\)\
\-\ which\\:\\ 0\\.05124882365750665\ \(0\)\
\-\ areas\\:\\ 0\\.05101332122534467\ \(0\)\
\-\ institutions\\:\\ 0\\.050950691000965255\ \(0\)\
\-\ spent\\:\\ 0\\.050174973278801105\ \(0\)\
\-\ vagal\\:\\ 0\\.049481070130893076\ \(0\)\
\-\ approximately\\:\\ 0\\.04794335625806034\ \(0\)\
\-\ patches\\:\\ 0\\.04775314209375419\ \(0\)\
\-\ brain\\:\\ 0\\.046840674815203695\ \(0\)\
\-\ commands\\:\\ 0\\.04681068157853572\ \(0\)\
\-\ renal\\:\\ 0\\.04679040003254774\ \(0\)\
\-\ prolongation\\:\\ 0\\.04598635855434031\ \(0\)\
\-\ neurologist\\:\\ 0\\.04560991389625055\ \(0\)\
\-\ when\\:\\ 0\\.045387548644216326\ \(0\)\
\-\ patch\\:\\ 0\\.04491601074834252\ \(0\)\
\-\ astrocytomas\\:\\ 0\\.04491601074834252\ \(0\)\
\-\ likely\\:\\ 0\\.044900462061633034\ \(0\)\
\-\ there\\:\\ 0\\.04484561621113685\ \(0\)\
\-\ however\\:\\ 0\\.044472762894711325\ \(0\)\
\-\ scars\\:\\ 0\\.04399554019857011\ \(0\)\
\-\ retardation\\:\\ 0\\.04399554019857011\ \(0\)\
\-\ your\\:\\ 0\\.04399554019857011\ \(0\)\
\-\ presented\\:\\ 0\\.04381607977083217\ \(0\)\
\-\ longstanding\\:\\ 0\\.04371524306605734\ \(0\)\
\-\ interestingly\\:\\ 0\\.04371524306605734\ \(0\)\
\-\ oct\\:\\ 0\\.04344638987827034\ \(0\)\
\-\ therapy\\:\\ 0\\.043171510489896474\ \(0\)\
\-\ cell\\:\\ 0\\.042982254690074134\ \(0\)\
\-\ perrla\\:\\ 0\\.042700008456427255\ \(0\)\
\-\ forehead\\:\\ 0\\.042700008456427255\ \(0\)\
\-\ ectopia\\:\\ 0\\.042700008456427255\ \(0\)\
\-\ move\\:\\ 0\\.042700008456427255\ \(0\)\
\-\ than\\:\\ 0\\.042593454125571535\ \(0\)\
\-\ these\\:\\ 0\\.042430275447368174\ \(0\)\
\-\ patients\\:\\ 0\\.042269093567236994\ \(0\)\
\-\ pcp\\:\\ 0\\.04202966879888797\ \(0\)\
\-\ stimulation\\:\\ 0\\.041421299171789744\ \(0\)\
\-\ more\\:\\ 0\\.04125866120155715\ \(0\)\
\-\ towards\\:\\ 0\\.041230387586355076\ \(0\)\
\-\ increased\\:\\ 0\\.040630922252650754\ \(0\)\
\-\ closely\\:\\ 0\\.040350951365791955\ \(0\)\
\-\ monitored\\:\\ 0\\.040350951365791955\ \(0\)\
\-\ noted\\:\\ 0\\.0398379249459272\ \(0\)\
\-\ others\\:\\ 0\\.03957523364362781\ \(0\)\
\-\ picture\\:\\ 0\\.03943048081601955\ \(0\)\
\-\ can\\:\\ 0\\.03942991073413203\ \(0\)\
\-\ cutaneous\\:\\ 0\\.03901438529443982\ \(0\)\
\-\ largest\\:\\ 0\\.038253618744491374\ \(0\)\
\-\ childhood\\:\\ 0\\.03801837986206872\ \(0\)\
\-\ conservatively\\:\\ 0\\.03779125430193183\ \(0\)\
\-\ case\\:\\ 0\\.0377483884659579\ \(0\)\
\-\ greatest\\:\\ 0\\.03757170102033256\ \(0\)\
\-\ requiring\\:\\ 0\\.03746460941633741\ \(0\)\
\-\ 2006\\:\\ 0\\.03746460941633741\ \(0\)\
\-\ lateral\\:\\ 0\\.037289215122136454\ \(0\)\
\-\ final\\:\\ 0\\.03685623978923919\ \(0\)\
\-\ follows\\:\\ 0\\.0367600922636622\ \(0\)\
\-\ managed\\:\\ 0\\.0367600922636622\ \(0\)\
\-\ surgical\\:\\ 0\\.0365193974177316\ \(0\)\
\-\ support\\:\\ 0\\.036479795131149434\ \(0\)\
\-\ hemispheres\\:\\ 0\\.036479795131149434\ \(0\)\
\-\ every\\:\\ 0\\.03638895246975983\ \(0\)\
\-\ continues\\:\\ 0\\.03586873569860947\ \(0\)\
\-\ atrophy\\:\\ 0\\.035543435578416875\ \(0\)\
\-\ callosum\\:\\ 0\\.03538661891916701\ \(0\)\
\-\ also\\:\\ 0\\.035342644129610204\ \(0\)\
\-\ feeding\\:\\ 0\\.0352334494916496\ \(0\)\
\-\ pituitary\\:\\ 0\\.03465408816180333\ \(0\)\
\-\ somewhat\\:\\ 0\\.03418585123688184\ \(0\)\
\-\ complication\\:\\ 0\\.034121597180569924\ \(0\)\
\-\ simple\\:\\ 0\\.03399493965144716\ \(0\)\
\-\ options\\:\\ 0\\.033870672030191534\ \(0\)\
\-\ six\\:\\ 0\\.03374870579396241\ \(0\)\
\-\ birth\\:\\ 0\\.03356988969132614\ \(0\)\
\-\ our\\:\\ 0\\.033282246223938376\ \(0\)\
\-\ versus\\:\\ 0\\.03322619491938127\ \(0\)\
\-\ vitals\\:\\ 0\\.03317061662725175\ \(0\)\
\-\ disorders\\:\\ 0\\.03317061662725175\ \(0\)\
\-\ main\\:\\ 0\\.032742108547580244\ \(0\)\
\-\ mental\\:\\ 0\\.032742108547580244\ \(0\)\
\-\ scattered\\:\\ 0\\.03269045347076303\ \(0\)\
\-\ though\\:\\ 0\\.032639200383052805\ \(0\)\
\-\ that\\:\\ 0\\.03260696564856466\ \(0\)\
\-\ much\\:\\ 0\\.03253787548400148\ \(0\)\
\-\ having\\:\\ 0\\.0323887523917786\ \(0\)\
\-\ those\\:\\ 0\\.03214748041075594\ \(0\)\
\-\ mother\\:\\ 0\\.03210026882125396\ \(0\)\
\-\ by\\:\\ 0\\.0319078463764686\ \(0\)\
\-\ numerous\\:\\ 0\\.03173428641879179\ \(0\)\
\-\ medications\\:\\ 0\\.03151546268452448\ \(0\)\
\-\ represent\\:\\ 0\\.03126212420010203\ \(0\)\
\-\ indicated\\:\\ 0\\.030899501138968784\ \(0\)\
\-\ affected\\:\\ 0\\.030899501138968784\ \(0\)\
\-\ neurological\\:\\ 0\\.030860415038891458\ \(0\)\
\-\ children\\:\\ 0\\.030782931927160806\ \(0\)\
\-\ cerebellar\\:\\ 0\\.030744529552859595\ \(0\)\
\-\ another\\:\\ 0\\.030744529552859595\ \(0\)\
\-\ underlying\\:\\ 0\\.030668390109099036\ \(0\)\
\-\ measures\\:\\ 0\\.03063064795118178\ \(0\)\
\-\ suggest\\:\\ 0\\.030518702108136897\ \(0\)\
\-\ addition\\:\\ 0\\.030408627314104528\ \(0\)\
\-\ characteristic\\:\\ 0\\.030372340784115076\ \(0\)\
\-\ diameter\\:\\ 0\\.030193847785388046\ \(0\)\
\-\ outside\\:\\ 0\\.030158722429954085\ \(0\)\
\-\ increase\\:\\ 0\\.030158722429954085\ \(0\)\
\-\ tube\\:\\ 0\\.030020064918405667\ \(0\)\
\-\ 90\\:\\ 0\\.030020064918405667\ \(0\)\
\-\ condition\\:\\ 0\\.030020064918405667\ \(0\)\
\-\ us\\:\\ 0\\.029884266529338697\ \(0\)\
\-\ done\\:\\ 0\\.029884266529338697\ \(0\)\
\-\ appear\\:\\ 0\\.029588586467259297\ \(0\)\
\-\ increasing\\:\\ 0\\.029588586467259297\ \(0\)\
\-\ term\\:\\ 0\\.029461317028024365\ \(0\)\
\-\ slightly\\:\\ 0\\.02930561264764098\ \(0\)\
\-\ 16\\:\\ 0\\.029274908682787416\ \(0\)\
\-\ results\\:\\ 0\\.029274908682787416\ \(0\)\
\-\ thin\\:\\ 0\\.029244347196241523\ \(0\)\
\-\ routine\\:\\ 0\\.029093631499477565\ \(0\)\
\-\ complex\\:\\ 0\\.028946287803018986\ \(0\)\
\-\ partial\\:\\ 0\\.028946287803018986\ \(0\)\
\-\ currently\\:\\ 0\\.028859438344039097\ \(0\)\
\-\ extremities\\:\\ 0\\.02855044404833349\ \(0\)\
\-\ cysts\\:\\ 0\\.028468629474077384\ \(0\)\
\-\ at\\:\\ 0\\.028380479334029787\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.02836110074211389\ \(0\)\
\-\ skin\\:\\ 0\\.027947726590984254\ \(0\)\
\-\ like\\:\\ 0\\.027922732297105082\ \(0\)\
\-\ its\\:\\ 0\\.027799164159524117\ \(0\)\
\-\ ventricle\\:\\ 0\\.027653879109318078\ \(0\)\
\-\ throughout\\:\\ 0\\.02762997349856108\ \(0\)\
\-\ tumors\\:\\ 0\\.02762997349856108\ \(0\)\
\-\ activity\\:\\ 0\\.027582421028205385\ \(0\)\
\-\ intact\\:\\ 0\\.02719151466675853\ \(0\)\
\-\ involvement\\:\\ 0\\.02719151466675853\ \(0\)\
\-\ cortical\\:\\ 0\\.02697196138515926\ \(0\)\
\-\ iv\\:\\ 0\\.026843658849681814\ \(0\)\
\-\ care\\:\\ 0\\.026843658849681814\ \(0\)\
\-\ identified\\:\\ 0\\.026635224095283624\ \(0\)\
\-\ cerebral\\:\\ 0\\.02602806146691188\ \(0\)\
\-\ now\\:\\ 0\\.025789212834586538\ \(0\)\
\-\ cause\\:\\ 0\\.025593663047403525\ \(0\)\
\-\ possible\\:\\ 0\\.02545500553585511\ \(0\)\
\-\ size\\:\\ 0\\.025437876817402817\ \(0\)\
\-\ recent\\:\\ 0\\.025437876817402817\ \(0\)\
\-\ followed\\:\\ 0\\.025369803978478548\ \(0\)\
\-\ back\\:\\ 0\\.02505573247178072\ \(0\)\
\-\ bilaterally\\:\\ 0\\.02505573247178072\ \(0\)\
\-\ long\\:\\ 0\\.024912032475848035\ \(0\)\
\-\ white\\:\\ 0\\.024786879283993712\ \(0\)\
\-\ past\\:\\ 0\\.024454488225159596\ \(0\)\
\-\ no\\:\\ 0\\.024433941276468127\ \(0\)\
\-\ known\\:\\ 0\\.024323201714417042\ \(0\)\
\-\ found\\:\\ 0\\.024308774570569895\ \(0\)\
\-\ such\\:\\ 0\\.024166215140214248\ \(0\)\
\-\ severe\\:\\ 0\\.023782722874675553\ \(0\)\
\-\ some\\:\\ 0\\.02363797004706729\ \(0\)\
\-\ years\\:\\ 0\\.0230292176138117\ \(0\)\
\-\ for\\:\\ 0\\.022773675318745117\ \(0\)\
\-\ syndrome\\:\\ 0\\.02264881859443079\ \(0\)\
\-\ abnormal\\:\\ 0\\.02257087699207845\ \(0\)\
\-\ focal\\:\\ 0\\.022472002913561433\ \(0\)\
\-\ time\\:\\ 0\\.0222680195635989\ \(0\)\
\-\ fluid\\:\\ 0\\.02169144077151533\ \(0\)\
\-\ enhancement\\:\\ 0\\.021623990409131186\ \(0\)\
\-\ t2\\:\\ 0\\.02161441078775848\ \(0\)\
\-\ lesions\\:\\ 0\\.021576231037167555\ \(0\)\
\-\ cm\\:\\ 0\\.021576231037167555\ \(0\)\
\-\ evidence\\:\\ 0\\.021324149677835233\ \(0\)\
\-\ mild\\:\\ 0\\.021296727062785768\ \(0\)\
\-\ who\\:\\ 0\\.02125127492563878\ \(0\)\
\-\ anterior\\:\\ 0\\.02097626440767833\ \(0\)\
\-\ associated\\:\\ 0\\.019801614361204083\ \(0\)\
\-\ most\\:\\ 0\\.019551980148153417\ \(0\)\
\-\ mri\\:\\ 0\\.0192845268941654\ \(0\)\
\-\ it\\:\\ 0\\.019230981977012774\ \(0\)\
\-\ exam\\:\\ 0\\.018912190426055932\ \(0\)\
\-\ may\\:\\ 0\\.018905842484810205\ \(0\)\
\-\ have\\:\\ 0\\.018767713734735524\ \(0\)\
\-\ but\\:\\ 0\\.01857786735487763\ \(0\)\
\-\ multiple\\:\\ 0\\.01837575437328122\ \(0\)\
\-\ contrast\\:\\ 0\\.018253949264124786\ \(0\)\
\-\ female\\:\\ 0\\.018128714939557602\ \(0\)\
\-\ lesion\\:\\ 0\\.018011354380373174\ \(0\)\
\-\ treatment\\:\\ 0\\.017896048592988555\ \(0\)\
\-\ within\\:\\ 0\\.01730306529867272\ \(0\)\
\-\ disease\\:\\ 0\\.01577007904712651\ \(0\)\
\-\ from\\:\\ 0\\.01492076436364177\ \(0\)\
\-\ not\\:\\ 0\\.014831298148870867\ \(0\)\
\-\ or\\:\\ 0\\.01306954261920798\ \(0\)\
\-\ right\\:\\ 0\\.012455636479847118\ \(0\)\
\-\ year\\:\\ 0\\.01157798758261106\ \(0\)\
